Sun Pharma Share Price Live Updates: Sun Pharma’s Current Price and Performance Metrics
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Profit by knowlytics
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Disclaimer: The content of this post is sourced from external sites and is for informational purposes only. All rights and…
Kedia Securities, backed by ace investor Vijay Kedia, acquired a fresh 1.45% stake in smallcap engineering firm Eimco Elecon during the June 2026 quarter. The stock has gained nearly 15% in the past month, while improving FII participation, strong fundamentals and a constructive technical setup continue to keep it on investors’ radar.
Prominent investors Ashish Kacholia and Madhusudan Kela have reduced their stakes in SG Finserve. This move follows a substantial 52% share price increase since the year began. Kacholia’s holding dropped below the disclosure threshold, indicating a likely exit from the company. Kela also marginally decreased his investment in the non-banking financial firm. SG Finserve reported…
HCL Technologies is investing up to Rs 3,500 crore in AI data centres to build a full-stack AI ecosystem spanning infrastructure, compute and managed services. While the phased investment could create a new growth engine, investors will closely watch capital deployment, returns and demand visibility before assigning meaningful value to the venture.
Cupid shares have delivered substantial investor returns, reaching 8,700% over three years. The company manufactures condoms and IVD kits, operating a facility near Nashik. Strong revenue and profit growth are supported by exports and portfolio expansion.